Skip to main
  1. Stocks
  2. Acadia Pharmaceuticals Inc.
  3. Forecast
ACAD

ACAD Stock Forecast & Price Target

ACAD Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 35%
Hold 24%
Sell 0%
Strong Sell 0%

Bulls say

Acadia Pharmaceuticals is supported by two durable commercial franchises, with Nuplazid generating $202.2M in 3Q26 and Daybue delivering a notable $140.1M beat, lifting full-year revenue guidance to $1.265B-$1.295B while the company ended 3Q26 with $976M in cash. Its positive outlook is further reinforced by Daybue’s accelerating Stix uptake, which has already reached more than 50% of U.S. patients and still appears to have room to expand, plus early European launch activity that could add another growth leg. Beyond the current base business, management’s pipeline offers meaningful optionality through remlifanserin and ACP-211, and even with higher-risk readouts ahead, the valuation appears to understate the resilience and scale of the existing revenue stream.

Bears say

Acadia Pharmaceuticals is viewed negatively because its valuation depends heavily on two commercial products, yet both face meaningful execution risk from slower-than-expected uptake, worsening reimbursement, and potential regulatory or clinical delays. Nuplazid could see flattening growth in Parkinson’s disease psychosis, while Daybue’s launch in Rett syndrome may stall, and the company also faces IP uncertainty, safety-signal risk, and competition from larger biopharma peers. Its pipeline adds little near-term comfort because key CNS programs, including ACP-204 in ADP and ACP-101 in hyperphagia in PWS, may fail or be delayed, with the remlifanserin trial already missing its primary endpoint at 60mg.

ACAD has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 35% recommend Buy, 24% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acadia Pharmaceuticals Inc. and is not a guaranteed prediction by Public.com or investment advice.

ACAD Analyst Forecast & Price Prediction

Get the latest ACAD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACAD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acadia Pharmaceuticals Inc. (ACAD) Forecast

Analysts have given ACAD a Buy based on their latest research and market trends.

According to 17 analysts, ACAD has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acadia Pharmaceuticals Inc. (ACAD)


ACAD Analyst Forecast & Price Prediction

Get the latest ACAD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACAD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ACAD stock data and trends